GlobeNewswire

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
27/04/2026
Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential. To date, more than 600 patients and [...]
Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026
27/04/2026
DURHAM, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, [...]
Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit
27/04/2026
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc. (NASDAQ: BLTE), (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics [...]
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months
27/04/2026
Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis Once-daily ZORYVE cream was well tolerated with a [...]
SBC Medical Announces Full-Scale Rollout of Aesthetic Healthcare-Focused Interpretation App "Talk Bridge" Across All Shonan Beauty Clinic Locations
27/04/2026
Strengthening English-Speaking Customer Experience Through Interpretation Infrastructure, Specialized Talent, and Digital Marketing IRVINE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings [...]
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
27/04/2026
WOBURN, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced multiple [...]
Vystar Plans Dividend Spin Off of RXAIR and Related Brands Following R3alm, Inc. Transaction
27/04/2026
Vystar Announces Strategic Direction for Vytex, FEC, and RXAIR BOSTON, MA, April 27, 2026 (GLOBE NEWSWIRE) -- Vystar Corporation (OTCQB: VYST) is focusing the majority of its resources on R3alm.com , which, is building [...]
PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01
27/04/2026
Definitive Agreement Targeted for Execution by June 2026 TORONTO, April 27, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) (“PharmAla” or the “Company”), a biotechnology company [...]
Hyperion DeFi Announces Participation in Upcoming Investor and Industry Conferences
27/04/2026
LAGUNA HILLS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S. publicly listed DeFi company building on Hyperliquid, today announced that [...]
KFSH Joins Milken Institute Global Conference 2026 in Beverly Hills, California, as a Silver Sponsor
27/04/2026
BEVERLY HILLS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH) will participate as a Silver Sponsor at the Milken Institute Global Conference 2026, taking place in [...]
Backed by Goldman Sachs, Urgent Care Provider Xpress Wellness Appoints New Chief Operating Officer to Support Continued Growth
27/04/2026
New COO Joe Willey brings experience leading large-scale, people-first organizations to support expanding access to care across rural and suburban communities OKLAHOMA CITY, April 27, 2026 (GLOBE NEWSWIRE) -- Xpress [...]
Siren Biotechnology Publishes Foundational AAV Immuno-Gene Therapy Data and Announces Presentations at ASGCT 2026
27/04/2026
SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Siren Biotechnology today announced the publication of its first peer-reviewed manuscript in Molecular Therapy Oncology , alongside upcoming presentations at the [...]
Addgene Reinforces Its Expanding Role in Research with New Brand
27/04/2026
Marked by decades of scientific partnership, Addgene’s evolution from a pioneering plasmid repository to a trusted resource spanning all stages of research drives refreshed brand WATERTOWN, Mass., April 27, 2026 (GLOBE [...]
Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform
27/04/2026
Raanana, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, [...]
Sharecare surpasses 1 million hours of home care delivered to Veterans through U.S. Department of Veterans Affairs Community Care Network
27/04/2026
Collaboration between Sharecare and Red Duke Strategies enables Veterans’ friends or family members to become certified professional caregivers, significantly improving both quality of and access to care through VA- [...]
Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
27/04/2026
Positive clinical results from Alcohol Use Disorder clinical trial may strengthen potential for eligibility for Breakthrough Therapy Designation Vancouver, Canada, April 27, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine [...]
BriaCell Announces Six Clinical Data Presentations at ASCO 2026
27/04/2026
Final randomized Phase 2 Bria-IMT™ survival and quality of life data to be presented Biomarker analyses from the ongoing Phase 3 study evaluating predictors of response PHILADELPHIA and VANCOUVER, British Columbia, [...]
Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill
27/04/2026
Builds Support for Accelerated Access to SkinJect® for Gorlin Syndrome patients with a Rare Autosomal Dominant Disease PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or [...]
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
27/04/2026
Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus paclitaxel alone in the key secondary endpoint of median progression-free [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum